Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR12075(B)] to TAF9
- Suitable for: WB, ICC/IF
- Reacts with: Mouse, Rat, Human
Product nameAnti-TAF9 antibody [EPR12075(B)]
See all TAF9 primary antibodies
DescriptionRabbit monoclonal [EPR12075(B)] to TAF9
Tested applicationsSuitable for: WB, ICC/IFmore details
Unsuitable for: Flow Cyt,IHC-P or IP
Species reactivityReacts with: Mouse, Rat, Human
Predicted to work with: Cow, Orangutan
Synthetic peptide corresponding to residues in Human TAF9, (Uniprot ID: Q16594)
- HeLa, A431, MCF-7 and K562 cell lysates.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab169784 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 29 kDa.|
For unpurified use at 1/100 - 1/250
RelevanceTAF9 functions as a component of the DNA-binding general transcription factor complex TFIID and the regulatory transcription complex SAGA. Binding of TFIID to a promoter (with or without TATA element) is the initial step in pre-initiation complex (PIC) formation. TFIID plays a key role in the regulation of gene expression by RNA polymerase II through different activities such as transcription activator interaction, core promoter recognition and selectivity, TFIIA and TFIIB interaction, chromatin modification (histone acetylation by TAF1), facilitation of DNA opening and initiation of transcription. SAGA influences RNA polymerase II transcriptional activity through different activities such as TBP interaction (SPT3 and SPT8) and promoter selectivity, interaction with transcription activators (GCN5, ADA2, ADA3, and TRA1), and chromatin modification through histone acetylation (GCN5).
- TAF9 RNA polymerase II, TATA box-binding protein-associated factor, 32kDa antibody
- MGC:1603 antibody
- MGC:3647 antibody
All lanes : Anti-TAF9 antibody [EPR12075(B)] (ab169784) at 1/1000 dilution
Lane 1 : HeLa cell lysate
Lane 2 : A431 cell lysate
Lane 3 : MCF7 cell lysate
Lane 4 : K562 cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : Goat anti-rabbit HRP at 1/2000 dilution
Predicted band size: 29 kDa
Immunocytochemistry/Immunofluorescence analysis of MCF-7 (human breast carcinoma) cells labelling TAF9 with purified ab169784 at 1/500. Cells were fixed with 4% Paraformaldehyde. An Alexa Fluor® 488-conjugated goat anti-rabbit IgG (ab150077) at 1/1000 dilution was used as the secondary antibody. Nuclei couterstained with DAPI (blue).
Secondary Only Control: PBS was used instead of the primary antibody as the negative control.
Immunofluorescence analysis of MCF7 cells, labeling TAF9 using ab169784 at a 1/100 dilution.
ab169784 has been referenced in 1 publication.
- Zeng P et al. Cancer-testis antigen HCA587/MAGEC2 interacts with the general transcription coactivator TAF9 in cancer cells. Mol Med Rep 17:3226-3231 (2018). PubMed: 29257297